Kato M, Okada K, Yamashina M, Tohma T, Ishiwata D, Higashi Y, Ohwada F
Department of Urology, Saitama Medical School.
Hinyokika Kiyo. 1993 Feb;39(2):131-4.
We investigated the prognostic factors in 138 patients with stage D2 prostatic cancer by univariate and multivariate analyses. Analysis was restricted to 8 pre-treatment parameters, that is, age, general condition (PS), pain, number of metastases on bone scan, acid phosphatase value, Gleason's primary pattern, secondary pattern, and nucleoli grading. In addition, 4 therapeutic modalities except routine endocrine therapy, that is, castration, oral administration of estramustine phosphate, of 5-fluorouracil (5-FU) or its analogue, and combination chemotherapy, during the whole treatment period were included in the analysis. Univariate analysis (Kaplan-Meier method) showed only PS to be a significant prognostic factor. Multivariate analysis (Cox's proportional hazard model) revealed that PS, Gleason's primary pattern, oral administration of 5-FU or its analogue and combination chemotherapy were significant prognostic factors. However, patients treated by combination chemotherapy had poorer prognosis and chi 2 values of combination chemotherapy was the highest among the four parameters cited above. These results suggested that the 8 pre-treatment parameters examined in this study were not sufficient for predicting the prognosis of each patient.
我们通过单因素和多因素分析，对138例D2期前列腺癌患者的预后因素进行了研究。分析仅限于8个治疗前参数，即年龄、一般状况（PS）、疼痛、骨扫描转移灶数量、酸性磷酸酶值、Gleason主要分级、次要分级以及核仁分级。此外，整个治疗期间除常规内分泌治疗外的4种治疗方式，即去势、口服磷酸雌莫司汀、5-氟尿嘧啶（5-FU）或其类似物以及联合化疗，也纳入了分析。单因素分析（Kaplan-Meier法）显示只有PS是一个显著的预后因素。多因素分析（Cox比例风险模型）表明，PS、Gleason主要分级、口服5-FU或其类似物以及联合化疗是显著的预后因素。然而，接受联合化疗的患者预后较差，且联合化疗的卡方值在上述四个参数中是最高的。这些结果表明，本研究中所检测的8个治疗前参数不足以预测每位患者的预后。
